# JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

> **NCT03538301** · PHASE2 · COMPLETED · sponsor: **Nitto Denko Corporation** · enrollment: 123 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** ND-L02-s0201 (Low Dose)
- **DRUG:** ND-L02-s0201 (High Dose)
- **OTHER:** Other: Placebo

## Key facts

- **NCT ID:** NCT03538301
- **Lead sponsor:** Nitto Denko Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-08-24
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03538301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03538301, "JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03538301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*